Carroll Financial Associates’s GSK GSK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q4 | $496K | Buy |
9,014
+352
| +4% | +$18.3K | 0.03% | 255 |
|
|
2021
Q3 | $413K | Sell |
8,662
-216
| -2% | -$10.8K | 0.02% | 270 |
|
|
2021
Q2 | $441K | Buy |
8,878
+3,895
| +78% | +$187K | 0.03% | 271 |
|
|
2021
Q1 | $222K | Buy |
4,983
+934
| +23% | +$42.4K | 0.01% | 378 |
|
|
2020
Q4 | $186K | Buy |
4,049
+3
| +0.1% | +$138 | 0.01% | 381 |
|
|
2020
Q3 | $190K | Sell |
4,046
-2,058
| -34% | -$103K | 0.01% | 352 |
|
|
2020
Q2 | $311K | Sell |
6,104
-292
| -5% | -$15K | 0.03% | 274 |
|
|
2020
Q1 | $302K | Buy |
6,396
+626
| +11% | +$33.4K | 0.03% | 255 |
|
|
2019
Q4 | $338K | Buy |
5,770
+886
| +18% | +$49.3K | 0.03% | 264 |
|
|
2019
Q3 | $260K | Sell |
4,884
-299
| -6% | -$15.4K | 0.02% | 313 |
|
|
2019
Q2 | $259K | Sell |
5,183
-131
| -2% | -$6.57K | 0.02% | 311 |
|
|
2019
Q1 | $277K | Sell |
5,314
-429
| -7% | -$21.4K | 0.03% | 272 |
|
|
2018
Q4 | $278K | Sell |
5,743
-267
| -4% | -$13.1K | 0.03% | 227 |
|
|
2018
Q3 | $301K | Buy |
6,010
+14
| +0.2% | +$711 | 0.03% | 230 |
|
|
2018
Q2 | $302K | Buy |
5,996
+110
| +2% | +$5.54K | 0.03% | 229 |
|
|
2018
Q1 | $287K | Sell |
5,886
-561
| -9% | -$26.1K | 0.03% | 235 |
|
|
2017
Q4 | $285K | Sell |
6,447
-391
| -6% | -$18.1K | 0.03% | 236 |
|
|
2017
Q3 | $347K | Sell |
6,838
-114
| -2% | -$5.78K | 0.04% | 204 |
|
|
2017
Q2 | $374K | Buy |
6,952
+28
| +0.4% | +$1.49K | 0.05% | 196 |
|
|
2017
Q1 | $364K | Buy |
6,924
+254
| +4% | +$12.9K | 0.05% | 183 |
|
|
2016
Q4 | $321K | Sell |
6,670
-54
| -0.8% | -$2.67K | 0.05% | 186 |
|
|
2016
Q3 | $362K | Buy |
6,724
+21
| +0.3% | +$1.15K | 0.05% | 170 |
|
|
2016
Q2 | $363K | Sell |
6,703
-231
| -3% | -$12.2K | 0.06% | 167 |
|
|
2016
Q1 | $351K | Buy |
6,934
+2,318
| +50% | +$115K | 0.07% | 164 |
|
|
2015
Q4 | $232K | Hold |
4,616
| – | – | 0.05% | 190 |
|
|
2015
Q3 | $235K | Buy |
4,616
+1,039
| +29% | +$54.1K | 0.05% | 176 |
|
|
2015
Q2 | $186K | Buy |
3,577
+1,095
| +44% | +$61.7K | 0.04% | 199 |
|
|
2015
Q1 | $143K | Buy |
2,482
+287
| +13% | +$16.5K | 0.06% | 162 |
|
|
2014
Q4 | $123K | Buy |
2,195
+231
| +12% | +$12.9K | 0.08% | 152 |
|
|
2014
Q3 | $112K | Sell |
1,964
-326
| -14% | -$20K | 0.03% | 201 |
|
|
2014
Q2 | $153K | Buy |
2,290
+332
| +17% | +$22.5K | 0.04% | 184 |
|
|
2014
Q1 | $131K | Buy |
1,958
+206
| +12% | +$13.9K | 0.04% | 186 |
|
|
2013
Q4 | $116K | Sell |
1,752
-35
| -2% | -$2.27K | 0.04% | 194 |
|
|
2013
Q3 | $112K | Buy |
1,787
+67
| +4% | +$4.31K | 0.04% | 189 |
|
|
2013
Q2 | $107K | Buy |
+1,720
| New | +$109K | 0.05% | 156 |
|
Other funds holding GSK
BCIM
Carroll Financial Associates's GSK Position: Q4 2021 in Review
Carroll Financial Associates increased its GSK (GSK) stake by 4.1% in Q4 2021, buying an estimated $18.3K and bringing the position to 9,014 shares worth $496K. The position accounts for 0.03% of the portfolio, ranked #255.
Carroll Financial Associates first reported a position in GSK in Q2 2013 and has held it in 35 quarters since. 919 funds tracked by Wall St. Rank hold GSK as of Q4 2021.
- Carroll Financial Associates held 9,014 shares of GSK worth $496K as of Q4 2021.
- Carroll Financial Associates bought 352 GSK shares in Q4 2021, an estimated $18.3K.
- GSK made up 0.03% of Carroll Financial Associates's portfolio in Q4 2021, its #255 holding.
- Carroll Financial Associates first reported a position in GSK in Q2 2013 and has held it in 35 quarters since.
- 919 funds tracked by Wall St. Rank held GSK as of Q4 2021.
Based on Carroll Financial Associates's 13F filing for Q4 2021, filed 6 Jan 2022.